Rekvina Laboratories Limited is an Indian pharmaceutical company headquartered in **Vadodara, Gujarat**. The company is currently navigating a transformative phase characterized by a significant shift in corporate control, a major strategic acquisition, and a comprehensive effort to resolve historical regulatory suspensions. The company operates exclusively within the **Pharmaceutical Formulations** segment, focusing on cost-effective synthesis and regulatory-compliant manufacturing. --- ### **Strategic Pivot: The Radiant Parenterals Acquisition** The company is undergoing a fundamental restructuring driven by the acquisition of **Radiant Parenterals Limited**. This move is designed to consolidate operations, expand the product portfolio, and achieve economies of scale. * **Acquisition Structure:** Rekvina entered into a Securities Exchange and Purchase Agreement (**SEPA**) to acquire **100%** of the equity share capital (**18,51,100 shares**) of Radiant Parenterals Limited. * **Transaction Mechanism:** The acquisition is executed via a **Share Swap** with a determined ratio of **2.5 Equity Shares** of Rekvina Laboratories for every **1 Equity Share** of Radiant Parenterals. * **Total Consideration:** The deal is valued at **₹ 4,62,77,500**, settled through the issuance of **46,27,750** new shares at a price of **₹ 10 per share**. * **Synergistic Goals:** The integration aims to merge distribution networks and manufacturing capabilities to increase market share in the parenteral and formulations space. --- ### **Corporate Structure & Capitalization** Following recent corporate actions and the proposed acquisition, the company’s capital base has been significantly expanded. | Feature | Details | | :--- | :--- | | **Listing Status** | Listed on **BSE Limited** (Security Code: **526075**; Symbol: **VINRKLB**) | | **Trading Status** | Currently **Suspended** (Revocation application filed **Nov 2024**) | | **Authorized Capital** | Increased to **₹ 6,00,00,000** (1.20 Crore Equity Shares of **₹ 5** each) | | **Paid-up Capital** | **₹ 3,01,40,000** (Pre-expansion); subject to increase via preferential issues | | **Face Value** | **₹ 5** per share (Note: Some filings indicate a transition to **₹ 10**) | | **Registered Office** | 36, Sampatrao Colony, Alkapuri, Vadodara - 390007 (Shifted **Oct 2024**) | --- ### **Change in Control and Open Offer Dynamics** The acquisition of Radiant Parenterals and subsequent share allotments have triggered mandatory **Open Offers** under **SEBI (SAST) Regulations**. * **The 2026 Open Offer:** An offer to acquire up to **28,90,100** shares (representing **26%** of the expanded capital) at **₹ 10 per share**. * **Alternative High-Value Offer:** Separate filings indicate a secondary offer scenario for **26,30,000 shares** at a significantly higher price of **₹ 2,830 per share**, with **₹ 186.22 Crores** deposited in an escrow account at **HDFC Bank**. * **Promoter Reclassification:** **Dhruvalkumar Patel** is set to be reclassified as a **Promoter**, exercising joint control. Post-transaction, the Promoter Group’s holding is projected to reach between **64.03%** and **90.03%**, depending on public acceptance levels. * **Minimum Public Shareholding (MPS):** If the offer results in public holding falling below **25%**, the company must implement a compliance plan to restore the public float as per **SEBI** mandates. --- ### **Operational Model & Manufacturing Strategy** Rekvina utilizes its infrastructure to balance proprietary product development with third-party services to maximize capacity utilization. * **Contract Research and Manufacturing Services (CRAMS):** Providing specialized synthesis and manufacturing for external pharmaceutical clients. * **Custom Manufacturing:** Tailoring formulations to specific client requirements to diversify revenue streams. * **Job Work Activities:** Utilizing idle manufacturing capacity for third-party processing to mitigate high fixed costs and interest burdens. * **R&D Initiatives:** Accelerated focus on improving cost competitiveness and ensuring facilities meet evolving global regulatory standards. * **Cost Rationalization:** Ongoing implementation of resource optimization and management controls to stabilize the financial floor. --- ### **Financial Performance & Funding Roadmap** The company has faced a period of severe financial stress, reporting **Rs. Nil** revenue from operations in **FY 2023-24** due to an economic slowdown and internal liquidity constraints. * **Profitability:** The company remains **loss-making**; consequently, **no dividend** was recommended for the financial year ended **March 31, 2025**. * **Capital Raising:** A preferential issue to non-promoters raised **₹ 46,00,000**, earmarked for: * **Working Capital:** **₹ 40,00,000** (6-month deployment timeline). * **General Corporate Purposes:** **₹ 6,00,000**. * **Investment Limits:** Shareholders have authorized a new limit under **Section 186** for loans and investments up to **₹ 10 Crore**. --- ### **Risk Matrix & Compliance Challenges** Investors should note that Rekvina is currently managing a high-risk profile related to historical defaults and market volatility. **1. Regulatory & Listing Risks** * **Trading Suspension:** Shares are currently suspended on the BSE. While a revocation application is pending, there is no guarantee of immediate liquidity. * **Historical Non-compliance:** Past failures include the lack of a **Compliance Officer**, missing **Independent Directors**, and non-implementation of a **Structured Digital Database (SDD)**. * **Outstanding Dues:** As of **April 2021**, the company owed over **₹ 57 Lakhs** in arrears for listing fees and penalties to the exchange. **2. Operational & Market Risks** * **Input Cost Volatility:** Rising prices for **energy, solvents, and raw materials** directly impact already thin margins. * **Debt Servicing:** The company is burdened by **high interest costs** and finance charges. * **Internal Controls:** Management is currently rebuilding internal control frameworks which were previously deemed inadequate for the company's scale. **3. Transactional Risks** * **Offer Withdrawal:** The Open Offer is contingent upon the completion of the **SPA/SSA**; any failure in statutory approvals could lead to a withdrawal of the offer under **Regulation 23(1)**. * **Payment Delays:** Potential litigation or regulatory stays could delay the disbursement of funds to shareholders participating in the Open Offer.